A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2019
At a glance
- Drugs RG 7880 (Primary) ; Vedolizumab
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Genentech
- 01 Feb 2019 Planned End Date changed from 13 May 2021 to 24 Sep 2021.
- 01 Feb 2019 Planned primary completion date changed from 15 Dec 2020 to 23 Apr 2021.
- 17 Aug 2018 Planned number of patients changed from 330 to 270.